

**Title:** Potential Lives Saved Through Widespread Global Availability of GLP-1 Receptor Agonists: A Modeling Study

**Authors:** David Brook\*, Peter A. Singer+

\* *Principal, DBK Consulting, david.dbkconsulting@gmail.com*

+ *Professor Emeritus, University of Toronto, petersingeroc@gmail.com*

**Abstract:** This model attempts to quantify the potential impact of GLP-1 receptor agonists (GLP-1) in reducing global mortality linked to obesity, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Using global population data, T2DM and obesity prevalence, cardiovascular risk, and mortality reduction from GLP-1s, we estimate that ~943,000 lives could be saved annually with widespread global access to GLP-1 receptor agonists for individuals with obesity and/or T2DM and CVD.

**Disclaimer:** The views expressed in this article are the authors' alone and do not represent the official position(s) of any affiliated institutions or funders.

**Sources of Support:** Funding for the development and validation of this model is from the Sandra Rotman Centre for Global Health, University Health Network, Toronto, Canada.

**Word Count:** 1550

**Introduction:** Obesity and T2DM are major risk factors for cardiovascular disease, the leading cause of mortality globally. GLP-1 receptor agonists, like semaglutide and tirzepatide, have been shown to effectively reduce body weight and improve glycemic control. Semaglutide has also been shown to reduce mortality (1, 2).

Recently, Pandey et al estimated the number of lives that could be saved by expanded access to weight loss drugs in the United States (3). Health equity advocates have also highlighted access disparities in obesity treatments for African Americans (4). However, to our knowledge there is no estimate of the number of lives that could potentially be saved globally if GLP-1s were more broadly available, nor an advocacy movement for global equitable access.

In this study, we developed a model to estimate the number of lives that could be saved globally through the widespread and equitable availability of GLP-1s. In developing this model, we drew on the most recent peer-reviewed sources to estimate the prevalence and impact on mortality of obesity, T2DM and cardiovascular disease, noting the disparate geographic scope, timespan and populations of these studies. We estimated reductions in all-cause mortality based on the findings of the SELECT and FLOW trials of semaglutide (1,2). These limitations introduce a level of uncertainty in the findings, however, our intention in building this model is not to provide a precise measure of potential benefits, but rather to better understand their magnitude. We also wanted to publicly post a simple and transparent model that others could improve, and update as new data becomes available.

## **Methods:**

**Model Description:** Using Microsoft Excel, we constructed a model to estimate annual lives saved by:

1. Calculating the global population over the age of 19.
2. Estimating the prevalence of obesity, T2DM and cardiovascular disease in this population.
3. Estimating the impact on mortality of obesity, T2DM and cardiovascular disease and combinations thereof.
4. Applying reductions in all-cause mortality associated with the use of GLP-1s.
5. Aggregating potential mortality reduction across global populations with obesity and/or T2DM and cardiovascular disease.

**Data Sources:** All data sources are referenced in the model (see Annex 1).

- **Global Population:** Based on estimates from the United Nations.
- **Prevalence of Obesity and Diabetes:** Data from the International Diabetes Federation and other public sources were used to estimate global obesity and diabetes rates among adult populations.
- **CVD Risk:** Cardiovascular disease prevalence among adult populations, in general, and among the population of obese adults and adults with T2DM. The associated mortality rates were integrated into the model to calculate the reduction in CVD-related deaths.

- **Obesity, Diabetes and CVD Mortality Impacts:** Data from the BMC Public Health, NCBI-NLM and other public sources were used to estimate the mortality impacts of obesity, T2DM and CVD, and permutations of the three, among adult populations.
- **Mortality Reductions from GLP-1:** Publicly available data from BMC Public Health, and from the SELECT and FLOW trials of semaglutide were used to estimate mortality reductions from GLP-1.

See **Annex 1** for the complete model including references and rationale for each of its element.

**Results:** The results of the model are summarized in **Table 1**.

**Table 1 – Potential Lives Saved from the Widespread Global Availability of GLP-1 Receptor Agonists**

CO-MORBIDITIES	GLOBAL POPULATION > 19	ESTIMATED MORTALITY RATE	REDUCTION in MORTALITY from GLP-1	EXPECTED DEATHS	EXPECTED DEATHS w GLP-1	LIVES SAVED
Population > 19 + T2DM + Obesity + CVD	125,069,050	2.1%	20%	2,628,106	2,102,485	525,621
Population > 19 + T2DM - Obesity + CVD	38,937,230	1.3%	20%	510,623	408,498	102,125
Population > 19 - T2DM + Obesity + CVD	112,365,701	1.5%	19%	1,659,978	1,344,583	315,396
Population > 19 - T2DM - Obesity + CVD	343,628,019	1.0%	19%	3,311,887	2,682,628	629,259
					+CVD +(T2DM and / or Obesity) including +CVD	943,142
						1,572,400

The model estimates that if GLP-1 Receptor Agonists were made available globally, approximately 943,000 lives could be saved annually in populations with T2DM and/or obesity, and cardiovascular disease. More than half (56%) of these lives saved are in people with both T2DM and obesity. An additional ~629,000 lives could be saved in people with neither of these risk factors if the relative risk reduction in this subgroup is the same as for those with either or both risk factor, but the evidence for effectiveness of GLP-1s in populations with CVD alone is not yet available.

**Discussion:** Our model estimates that widespread global availability of GLP-1 receptor agonists could save approximately 943,000 lives annually. This figure underscores the profound public health impact these drugs could have, particularly in reducing all-cause mortality associated with cardiovascular disease (CVD) deaths, obesity and T2DM. Currently, however, the benefits of GLP-1s are concentrated in high-income countries, with limited access in low- and middle-income countries (LMICs).

This estimate of lives saved from GLP-1s falls between the estimated lives saved from childhood vaccines of 154 m lives over 50 years (3 million per year), and HIV drugs of 16.5 m lives over 20 years (0.825 million per year) (5, 6). As such, equitable access to GLP-1s represents an opportunity to save lives on a large scale, emphasizing the need for urgent action to expand access to these treatments.

Countries with the most potential lives saved are populous countries with high numbers of people with diabetes and obesity: China, India, US, Pakistan, and Brazil (7, 8). Those with the greatest potential reduction in prevalence are Pacific small island developing states with obesity prevalence up to 70% (8). Focusing on both is essential if we want equity among countries.

From a public health policy perspective, our model also shows that targeting those with both T2DM and obesity could be impactful, because of their high baseline event rates. And that developing evidence on the group with CVD but no T2DM or obesity could also be impactful, because of the large population in this subgroup.

While our model provides a useful estimate of the potential impact of GLP-1s on all-cause mortality in target populations, it has limitations. The mortality impacts of obesity, T2DM, and CVD are estimated based on the best available peer-reviewed evidence, but further refinement will be needed as more data becomes available. Additionally, rates of reductions in mortality are based on publicly available data from a limited number of trials of semaglutide, which do not provide data on its impact on all combinations of co-morbidities. All-cause mortality was a secondary outcome in these trials. Finally, the distribution of imputed risk in the population may not precisely match the participants in the clinical trials. This is a global model, and a country-by-country analysis may provide greater precision and added insights.

We used conservative figures in our estimation of mortality benefit. For example, the FLOW trial was a randomized trial of people with diabetes (and chronic renal failure) which showed a reduction in all-cause mortality of 20% (2). A retrospective cohort study of use of GLP1s in Taiwan showed a reduction in all-cause mortality of 52% (9). We used the more conservative figure of 20%; had we used the higher figure our lives saved estimate would be larger. At this point, it's unclear as to why the two values differ to the extent that they do. In the absence of more rigorous analysis, we made the conservative decision to use the lower figure from the randomized trial in our model.

Newer GLP-1s such as tirzepatide, often in combination with GIP and Glucagon receptor effects, have been shown to have even more significant effect on weight loss, although whether this leads to greater reductions in all-cause mortality is currently unknown. Moreover, GLP-1s are also being studied (and show preliminary but promising results) in the treatment of a wider range of conditions beyond CVD. (10)

Our goal was not to provide a comprehensive model of reducing mortality; that has been done recently in an outstanding analysis (11). From a policy perspective, some will argue that existing interventions such as taxes on sugar sweetened beverages, front of package labelling, and regulation of ultra-processed foods are more acceptable and/or cost-effective approaches to reduce mortality from obesity, T2DM and CVD in LMICs. There is evidence that these approaches are effective but, in many countries, they are already being used and obesity and T2DM rates continue to rise. This suggests the need for further interventions to curb and, ideally, reverse these rates.

Others will argue that availability of less expensive cardiovascular drugs such as anti-hypertensives should be prioritised instead of GLP-1s. Since the mechanisms of all these treatments are independent, and since currently available approaches are not stemming the rise in obesity and T2DM (and presumably the corresponding mortality) in most countries, we suggest the broader and more equitable GLP-1 access should also be pursued. Indeed, there is early evidence that in the US, the introduction of GLP1s has led to “peak obesity,” reversing this trend for the first time (12).

Modelling the effects of widespread global access is not the same as providing it. There are multiple barriers to access that would need to be overcome, including manufacturing, affordability, finance, regulatory, and intellectual property. While beyond the scope of this paper, we note the dynamic aspects of this market, including the expiry of the patent on semaglutide in India and China in 2026 (13, 14), with domestic firms preparing to manufacture it.

The precautionary principle suggests that, even in the face of uncertainty, immediate action should be taken to expand access to GLP-1s. Delaying broader access to these drugs risks could lead to the unnecessary loss of up to a million lives each year. While future trials and research may refine our understanding of these drugs' impact and, hence, their most impactful deployment, the urgency to act now is clear.

**Conclusion:** Expanding global access to GLP-1 receptor agonists offers a unique opportunity to reduce mortality associated with obesity, T2DM and CVD. Our model, which estimates 943,000 lives saved annually, highlighting the critical importance of overcoming barriers to access. Through innovative financing, advocacy, and global cooperation, the world can seize this opportunity to save lives on an almost unprecedented scale.

**Annex 1:** All-World Model - Potential Lives Saved from GLP1 (CVD only) – Oct 2024 Preprint

**Acknowledgments:** Thank you to colleagues at World Obesity Federation, Ole Frithjof Norheim, Haidong Wang and another reviewer for feedback and guidance on data sources and on the model, and to Jocalyn Clark for reviewing an earlier version of this paper.

**Disclosures:** David Brook works part-time with Gilbert's Solutions ([gilbertslaw.ca](http://gilbertslaw.ca)) that has received advisory fees from Novo Nordisk but not for the development of this global model. Peter Singer owns shares of Eli Lilly and Novo Nordisk.

An initial draft of this paper was developed using ChatGPT-4.

## References:

1. Lincoff MA, Brown-Frandsen K, Calhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med* 2023;389(24):2221-32.
2. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med* 2024; 391: 109-21.
3. Pandey A, Ye Y, Wells CR, Singer BH, Galvani AP. Estimating the lives that could be saved by expanded access to weight loss drugs. *PNAS* 2024; 121: e2412872121.

4. Sharpton A. The next balancing act in health equity: obesity. Washington Post, August 14, 2024. <https://www.washingtonpost.com/opinions/2024/08/14/medicare-obesity-drugs-black-americans/>
5. Shattock AJ, Johnson HC, SIM SY, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet; 2024: 2307-16.
6. UNAIDS. Global roll-out of HIV treatment has saved millions of lives. 2021 Sep 6. Available from: [https://www.unaids.org/en/resources/presscentre/featurestories/2021/september/20210906\\_global-roll-out-hiv-treatment](https://www.unaids.org/en/resources/presscentre/featurestories/2021/september/20210906_global-roll-out-hiv-treatment)
7. International Diabetes Federation. (2021). IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation. Available at: <https://diabetesatlas.org> [Accessed 30 Oct. 2024].
8. World Obesity Federation. Global Obesity Observatory. 2024. Available from: <https://data.worldobesity.org/rankings/>
9. Yen, FS., Hou, MC., Wei, J.CC. et al. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med22, 8 (2024). <https://doi.org/10.1186/s12916-023-03228-4>.
10. Drucker, D. J., (2024) The benefits of GLP-1 drugs beyond obesity. *Science*. [doi.org/10.1126/science.adn4128](https://doi.org/10.1126/science.adn4128).
11. Jamison DT, Summers LH, Chang AY, et al. Global health 2050: the path to halving premature death by mid-century. Lancet 2024; [https://doi.org/10.1016/S0140-6736\(24\)01439-9](https://doi.org/10.1016/S0140-6736(24)01439-9).
12. Murdoch-Burns J. We may have passed peak obesity. Financial Times, October 3, 2024.
13. Patentlawyermagazine.com. (2024). Ozempic's impending patent expiry spurs development of biosimilars in mainland China. [online] Available at: <https://patentlawyermagazine.com/ozempics-impending-patent-expiry-spurs-development-of-biosimilars-in-mainland-china/> [Accessed 30 Oct. 2024]
14. The Pharma Letter. (2024). India's PLI scheme sets stage for semaglutide production in 2026. [online] Available at: <https://www.thepharmaletter.com/india-pli-scheme-sets-stage-for-semaglutide-production-in-2026> [Accessed 30 Oct. 2024]